SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending due to the expansion of its partnership with NVIDIA, which integrates its safety-critical QNX OS into advanced edge AI systems for robotics, medical devices, and industrial applications. The community is actively discussing a major turnaround for the stock, with long-term investors celebrating the shift from a 'meme stock' narrative to one grounded in fundamental growth and industrial AI dominance.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is facing intense volatility and accusations of a coordinated pump-and-dump scheme, sparking a polarized debate among community members over whether the asset is a scam or a potential short-squeeze candidate. Traders remain divided as the project denies involvement in manipulation while investigators and exchange probes monitor the token's massive price swings.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing a massive, extended short squeeze driven by high institutional concentration and limited share availability, leading to intense speculation and volatility. The community remains deeply divided, with bulls riding the momentum while bears warn of an inevitable correction and emphasize the significant risks involved in trading such a parabolic move.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group Inc. is under intense selling pressure as investors react to continued share dilution and concerns over cash burn, with the community actively debating whether the company represents a deep-value opportunity or a failing venture destined for further restructuring. While some traders are attempting to catch a bottom, citing the potential of its technology and strategic partnerships, many are focused on the stock's significant decline and questioning the long-term viability of its business model.

Alaska Air Group, Inc. is a holding company, which engages in the provision of air transportation services. It operates through the following segments: Alaska Airlines, Hawaiian Airlines, and Regional. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo. The Hawaiian Airlines segment refers to scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. The Regional segment consists of Horizon's and other third-party carriers’ scheduled air transportation on E175 aircraft for passengers under CPAs. The company was founded in 1985 and is headquartered in Seattle, WA.

Alaska Air Group Inc.

Alaska Air Group is capturing significant attention as investors weigh the company's long-term integration strategy and international expansion against industry-wide pressures from volatile fuel costs and geopolitical uncertainty. While some in the community highlight strong revenue growth and forward bookings as indicators of a resilient recovery, others remain skeptical, citing suspended full-year guidance and the competitive challenges of high operational expenses.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is experiencing a shift in market sentiment following the surprise announcement that CEO Tim Cook will transition to Executive Chairman, with hardware engineering leader John Ternus set to take over as CEO in September. Investors are closely monitoring the leadership transition and the company's competitive position in AI, while the stock shows notable resilience amidst community debate over future innovation and strategic direction.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing high volatility driven by a presidential executive order aimed at expediting FDA reviews for psychedelic drugs like ibogaine. The community is sharply divided, with bulls pointing to the company's GMP-compliant supply chain and potential federal funding, while bears warn of the company's history of stock dilution and speculative, micro-float market dynamics.

Maase, Inc. engages in the provision of intelligent technology-driven family and enterprise services. It operates through the following business segments: Insurance Agency and Wealth Management. The Insurance Agency segment involves in providing agency services for distributing life and non-life insurance products on behalf of insurance companies. The Wealth Management segment offers financial advisory, investment planning, and asset management services for individuals, families, and corporate clients, utilizing data-driven insights and digital platforms to optimize financial outcomes. The company was founded by Hai Feng Yu on August 6, 2018, and is headquartered in Guangzhou, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

MAAS is trending as speculative traders and community members debate its volatility, grouping it with other low-float Chinese stocks amid aggressive intraday price swings. The primary discourse centers on its recent acquisition of an AI developer and ongoing battles between long-term holders and short sellers as the community scrutinizes its growth narrative.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing significant market interest and intense community debate as the stock attempts to reclaim key technical support levels amid ongoing speculation about potential AI partnerships. Investors are closely monitoring the stock's price action and institutional flows, with many discussing the recent large-scale insider share purchases as a signal of long-term confidence despite broader volatility in the ad-tech sector.

LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The firm combines virtual medical treatment with prescription medications and over-the-counter products. It operates through the Telehealth and WorkSimpli segments. The company was founded by Justin Schreiber on May 24, 1994 and is headquartered in New York, NY.

LifeMD Inc

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up

BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of +17.71% and +80.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Biogen Gears Up to Report Q2 Earnings: Here's What to Expect

Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.

What Makes Sage Therapeutics (SAGE) a New Buy Stock

Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

JPMorgan cut its price target on Sage Therapeutics to $8.5 from $11 based on the recently announced buyout by Supernus Pharmaceuticals, representing an 8.5% downside from the last close.The research firm maintained a 'Neutral' rating on the stock.Last week, Supernus said it would acquire Sage for $8.5 per share in cash, plus a contingent value right (CVR) worth up to $3.5, based on commercial milestones for Zurzuvae, an FDA-approved treatment for postpartum depression co-developed with Biogen.&nbsp;The total transaction value of up to $12 per share reflects a 79% premium to Sage’s last closing price before the announcement.The deal, expected to close in the third quarter of 2025, is intended to expand Supernus’ neuropsychiatry portfolio and&nbsp;could reduce annual costs by up to&nbsp;$200 million.The company also guaranteed a cash payout at closing, excluding value from the CVR, which remains contingent on future sales performance.&nbsp;Several other firms adjusted their price targets in response to the Supernus deal: Piper Sandler lowered its target to $8.50 from $9,&nbsp;while Truist raised its target to $9 from $8&nbsp;and Canaccord increased its target to $8.50 from $8, each maintaining a ‘Hold’ or ‘Neutral’ rating.&nbsp;BofA removed its rating altogether, stating that Sage shares are no longer trading on fundamentals following the acquisition announcement.H.C. Wainwright noted the $22.4 million breakup fee may not be large enough to prevent a competing offer, particularly from Biogen, which already co-commercializes Zurzuvae with Sage in the U.S.In January, Sage Therapeutics’ board&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/biib-stock-gains-onfda-nod-for-leqembi-dosing/chblEfgRYE">unanimously rejected</a> Biogen's unsolicited offer to acquire all outstanding shares for $7.22 per share.&nbsp;The company said the offer “significantly undervalued” Sage and was not in the best interest of shareholders.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.Shares of Sage Therapeutics closed up 1.9% at $9.3 on Friday. The stock has risen 60.9% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a smartphone and on a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms

Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen.

Equity

Supernus Pharmaceuticals, Inc. (SUPN) on Monday announced its intent to <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.supernus.com/news-releases/news-release-details/supernus-pharmaceuticals-acquire-sage-therapeutics-strengthening">acquire</a> Sage Therapeutics, Inc. (SAGE) for up to $795 million. SAGE stock traded 34% higher on Monday morning following the announcement.Under the terms of the deal, Supernus intends to acquire Sage for a total consideration of $12 per share in cash, including $8.50 per share payable at closing and a contingent value right (CVR) worth up to $3.50 per share in cash. The CVR is payable upon achieving certain net sales and commercial milestones, the companies said.The total consideration represents a premium of about 79% from SAGE’s closing price of $6.7 on Friday.The transaction is expected to close in the third quarter of 2025 and strengthen Supernus’ neuropsychiatry portfolio with the addition of Zurzuvae, the only oral medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with postpartum depression.Zurzuvae was co-developed by Sage and Biogen, Inc. (BIIB). Through a collaboration agreement with Biogen, Supernus will report collaboration revenue that is 50% of the total net revenue Biogen records for Zurzuvae in the U.S.In 2024 alone, Sage recorded a collaboration revenue of $36.1 million from net sales of Zurzuvae.Jack Khattar, President and CEO of Supernus Pharmaceuticals, said the acquisition augments the company’s growth profile by adding a fourth growth product to its portfolio, in addition to Qelbree, Onapgo, and Gocovri.The acquisition is also expected to be significantly accretive in 2026, with cost synergies of up to $200 million on an annual basis, the companies said.On Stocktwits, retail sentiment around SUPN jumped from ‘neutral’ to ‘bullish territory over the past 24 hours, while chatter increased from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_16_at_10_18_03_AM_png_8f57b78080.webp" alt="Screenshot 2025-06-16 at 10.18.03 AM.png" width="625" height="68"><figcaption>SUPN's Sentiment Meter and Message Volume as of 10:15 a.m. ET on June 16, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment around SAGE increased from ‘neutral’ to ‘extremely bullish’ territory while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_16_at_10_24_57_AM_png_4d871e71b4.webp" alt="Screenshot 2025-06-16 at 10.24.57 AM.png" width="628" height="67"><figcaption>SAGE's Sentiment Meter and Message Volume as of 10:20 a.m. ET on June 16, 2025 | Source: Stocktwits</figcaption></figure>This year, <a href="https://stocktwits.com/symbol/SAGE">SAGE stock</a> has risen 56% while <a href="https://stocktwits.com/symbol/SUPN">SUPN stock</a> fell about 10%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/trump-organization-enters-telecom-market-touts-us-made-phone/chlntPmRRR8">Trump Organization Enters Telecom Market, Touts US-Made Phone Amid President’s Push To Reshore Smartphone Production</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics

Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash.

Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?

Biogen Inc. shares climbed 1.7% on Monday afternoon, reaching a nearly two-week high, as positive regulatory news countered fallout from a rejected acquisition proposal.Sage Therapeutics announced its board had unanimously rejected Biogen's unsolicited Jan. 10&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sage-stock-soars-on-biogen-bid/chGN0nXRNV">offer</a> to acquire all outstanding Sage shares for $7.22 per share.&nbsp;The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.Sage's board also revealed plans to explore strategic alternatives, cautioning that a transaction is not guaranteed.&nbsp;Meanwhile, Sage reaffirmed its commitment to establishing Zurzuvae as the standard treatment for postpartum depression.&nbsp;Biogen, which co-markets Zurzuvae, had argued that full ownership would aid its rollout but expressed little interest in Sage's broader pipeline when it placed its bid.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BIIB_sentiment_and_message_volume_Jan_27_d1b89b799f.png" alt="BIIB sentiment and message volume Jan 27.png" width="1318" height="324"><figcaption>BIIB sentiment and message volume Jan 27 as of 1:20 pm ET | source: Stocktwits</figcaption></figure>Following the rejection, retail sentiment for Biogen turned 'bearish' on Stocktwits, with increased message volume reflecting investor concerns about the deal's implications.<stembedurl>https://stocktwits.com/Gito/message/601644664</stembedurl><stembedurl>https://stocktwits.com/Scanners_Free/message/601610361</stembedurl>However, Biogen received a significant boost as the FDA on Sunday approved a supplemental biologics license application for Leqembi, developed in collaboration with Eisai Co. Ltd.&nbsp;The new label allows for once-every-four-weeks intravenous maintenance dosing following an 18-month initiation phase of biweekly treatments.Leqembi, used to treat early-stage Alzheimer's disease, addresses patients with mild cognitive impairment or mild dementia.&nbsp;The updated dosing regimen is expected to improve patient compliance while enhancing convenience.However, Biogen's challenges remain stark; the stock has lost nearly 40% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail

The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.

Sage Therapeutics Inc. stock surged over 37% on Monday, reaching its highest level since October, following confirmation of an unsolicited takeover bid from Biogen Inc.&nbsp;The rally sets Sage on track for its&nbsp;most significant percentage gain since Jan. 7, 2019. The stock is also on course to snap a three-day losing streak&nbsp;amidst heavy trading and retail sentiment turning more optimistic.Biogen has offered to acquire the remaining 90% of Sage,&nbsp;which it does not own, for $469 million, or $7.22 per share, representing a premium of over 30% from Sage’s Friday closing price.&nbsp;Sage’s Board of Directors announced they would review the nonbinding proposal carefully to decide the best course of action for the company and its shareholders.The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression.&nbsp;Biogen, which currently shares revenue from Zurzuvae with Sage, argued in an SEC-filed letter that sole ownership would improve the drug’s rollout but notably omitted any interest in Sage’s broader pipeline, according to Barron’s.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SAGE_sentiment_meter_and_message_volume_Jan_13_53ad1877e5.png" alt="SAGE sentiment meter and message volume Jan 13.png" width="1318" height="324"><figcaption>SAGE sentiment meter and message volume Jan 13 as of 2 pm ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned more ‘bullish’ for Sage, with shares surpassing Biogen’s implied offer price, while sentiment for Biogen turned ‘extremely bullish’ as its stock edged higher.<stembedurl>https://stocktwits.com/Dodge2/message/599833394</stembedurl><stembedurl>https://stocktwits.com/Ranger300/message/599788035</stembedurl>Analysts expressed mixed views.&nbsp;Mizuho analyst Uy Ear argued that Biogen’s bid undervalues Sage, suggesting the implied enterprise value is zero, as the company is set to end the fourth quarter with $500 million in net cash.&nbsp;Sage held $569 million in cash and equivalents as of Sep. 30, 2024.The offer also overlooks any valuation for Zurzuvae’s postpartum depression potential or Sage’s early-stage pipeline, including SAGE-319, the analyst added.Meanwhile, Truist analysts noted Zurzuvae’s slow start but predicted a steady launch trajectory, saying “the hardest part of commercialization could be in the rear-view.”Over the past year, Sage’s stock has declined more than 72%, while Biogen shares have dropped nearly 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of biopharmaceutical company Sage Therapeutics is seen on a smartphone and on a PC screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In

The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression.

Macy's, Abercrombie and Moderna fall premarket; Sage soars

Investing.com -- US stock futures fell Monday, as investors fretted that the hot jobs report will prompt the Federal Reserve to hold back on rate cuts this year.

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

SAGE
Sage Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SAGE News

SAGESage Therapeutics Inc